StockMirror — Stock Screener

TRUALT Q2 FY27 Results & Earnings Analysis

Sentiment: Neutral (Confidence: medium)

Earnings Summary

TruAlt Bioenergy reported strong Q2 FY27 revenue growth of 606% YoY to INR811 crores and a PAT turnaround to INR35 crores, driven by higher ethanol volumes and capacity utilization. However, EBITDA margin contracted sharply QoQ to 14.03% due to a 25-30% rise in maize prices. Management expects margin recovery from Q3 as raw material season improves and CBG plants ramp up. The company is focused on CBG expansion (250 TPD target) and SAF, supported by government policies, while managing raw material volatility and working capital. Key risks include El Nino impact, regulatory changes, and margin pressure.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management emphasized revenue growth through volume expansion and CBG, while also focusing on margin recovery through raw material optimization, capacity utilization, and cost control.

About TruAlt Bioenergy Limited

TruAlt Bioenergy Limited (TRUALT) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More